SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors rotate into its QNX division, which is increasingly positioned as the critical safety-certified operating system for the emerging Physical AI and robotics sectors. The community is actively discussing recent analyst price target upgrades, positive institutional momentum, and the high-growth potential of the Alloy Kore platform ahead of upcoming earnings.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending following the announcement of a joint research agreement with Honda to develop solid-state battery technology and manufacturing processes. Community sentiment is mixed as investors weigh the significance of a major OEM validation against the reality that the partnership focuses on research rather than immediate mass production.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is surging following record quarterly revenue and the milestone achievement of positive operating cash flow, signaling a significant transition toward profitability. Investors are actively discussing the company's strategic pivot into semiconductor-based licensing and its growing AI-integrated imaging partnerships.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as the community debates the geopolitical and economic ramifications of a new memorandum of understanding between the U.S. and Iran. Discussions are heavily focused on the terms of the deal, the potential for market manipulation via official social media channels, and the broader concerns regarding current economic stability.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is experiencing significant market interest driven by the accelerating adoption of its da Vinci 5 platform and robust global procedure growth. The community remains largely bullish on the company's long-term dominance in the robotic surgery space, focusing on its wide competitive moat and high recurring revenue, even as some traders debate the stock's current valuation premium.

Spacecoin is a satellite-based decentralized internet network that aims to provide reliable, permissionless connectivity across the globe. It is building a constellation of blockchain-enabled small satellites in low-Earth orbit to transmit data back to the Earth without heavily relying on traditional internet infrastructure such as cell towers and fiber-optic cables. The goal is to provide a reliable lifeline connection for the 2.6 billion people globally who have never connected to the Internet and an additional 3.5 billion who live with restricted access.  Spacecoin plans to offer services in its target countries of Nigeria, Indonesia, and India for as low as $1-2 per month per user. The network works as an open system where anyone can add satellites. The first satellite launched in December 2024, with three more planned for October 2025.

Spacelens

The community is actively debating the connection between the Spacelens token and the highly anticipated SpaceX IPO, with many investors speculating on how market sentiment toward Elon Musk and broader space-tech trends will impact performance. Conversations are split between those viewing the coin as a long-term play on decentralized satellite technology and others expressing frustration over price volatility and perceived insider influence.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors react to strong quarterly growth and ongoing speculation regarding potential strategic interest or merger activity. The community is actively debating the company's valuation relative to its revenue expansion, the impact of pending litigation, and the significant institutional accumulation seen in recent filings.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is facing intense downward pressure and volatility as investors weigh a strong quarterly earnings report against concerns that emerging AI agentic tools could disrupt its core SaaS business model. While some in the community see the stock as a deeply undervalued 'steal' supported by strong cash reserves and institutional accumulation, others are aggressively betting on further downside, citing an ongoing rotation out of traditional software and fears that AI-native startups will erode future growth.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is experiencing extreme volatility and intense social media scrutiny, with the community sharply divided between vocal critics labeling it a fraudulent pump-and-dump scheme and bullish investors betting on the company's drone software technology and potential defense contracts. Investors remain highly active in tracking the stock's sharp price swings and low-volume fluctuations, focusing heavily on its connection to the defense sector and ongoing speculation regarding future government partnerships.

XYO is the original and one of the largest Decentralized Physical Infrastructure Networks (DePIN), boasting over 10 million nodes and consistently leading DePIN in both scale and revenue generation. Launching its Mainnet ahead of any other DePIN, XYO specializes in collecting and validating real-world data, bridging it seamlessly to Web3 and Web2 companies across AI, geolocation, and other critical data sectors. At the core of XYO are Proof of Location and Proof of Origin technologies, enabling accurate validation of real-world data for innovative use cases such as Real-World Asset (RWA) tracking, DePIN applications, real-world gaming, and treasure hunts. Recently, XYO expanded its ecosystem by launching the XYO Layer One blockchain, purpose-built to support the intensive data demands of DePIN, RWA, AI, and similar data-driven industries. XYO employs a unique dual-token model: XYO Token: An externally traded token supporting the DePIN ecosystem, rewards, staking, and governance, enhancing overall ecosystem value and scarcity.   XL1 Token: Internal to the XYO Layer One blockchain, facilitating transactions, gas fees, and other blockchain-specific use cases. The dual-token economics are strategically designed to increase scarcity and promote sustainable growth. The XYO token is available on major exchanges, including Coinbase. The XL1 token will launch publicly later in 2025. To accelerate network adoption and growth, XYO created the popular COIN app. Beyond the XYO Foundation, the team founded the U.S.-based, for-profit entity XY Labs Inc., notable as the first U.S. crypto company qualified by the SEC for a Regulation A offering, permitting share sales to both accredited and non-accredited investors. XY Labs further stands out as one of the pioneering U.S. companies to tokenize and publicly list its shares. These tokenized shares trade as $XYLB on the tZERO ATS, positioning XY Labs prominently in the growing wave of Real-World Asset (RWA) tokenization.

XYO Network

XYO is currently experiencing heightened social media engagement driven by intense community debate over its price performance and recurring speculation regarding potential partnerships or project announcements. Investors remain deeply divided, with some accumulation occurring at current levels based on long-term conviction in the network's data validation technology, while others express frustration over stagnant price action and what they describe as a pattern of pump-and-dump activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

In the most recent trading session, AbbVie (ABBV) closed at $216.49, indicating a -2.14% shift from the previous trading day.

AbbVie Declares Quarterly Dividend

AbbVie Declares Quarterly Dividend AbbVie Declares Quarterly Dividend PR Newswire NORTH CHICAGO, Ill., June 18, 2026 NORTH CHICAGO, Ill., June 18, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share. The cash dividend...

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet

Based on the average brokerage recommendation (ABR), AbbVie (ABBV) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVDERM for the Improvement of Neck Appearance

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVDERM for the Improvement of Neck Appearance Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVDERM for the Improvement of Neck Appearance PR Newswire IRVINE, Calif., June 16, 2026 SKINVIVE by JUVDERM is now the first...

AbbVie (ABBV) Rises Higher Than Market: Key Facts

AbbVie (ABBV) closed at $227.73 in the latest trading session, marking a +1.32% move from the prior day.

AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.

Key PointsThe company is expanding both approved and pipeline therapies...

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA/VENCLYXTO (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA/VENCLYXTO (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA/VENCLYXTO (venetoclax) in First-Line...

Will Skyrizi & Rinvoq Continue to Drive AbbVie's Topline Through 2026?

ABBV's Skyrizi and Rinvoq post strong Q1 growth, lift 2026 sales outlooks and sustain momentum through new indications.

Can Linzess Continue Driving IRWD's Revenue Growth Through 2026?

Ironwood sees Linzess momentum as strong demand, a pediatric expansion and pricing changes are expected to boost revenues and profit in 2026.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

ABBV Stock Gains On Winning FDA Approval For Rare Blood Cancer Drug

Equity

Neutral Sentiment

Track ABBV stock price, charts, news and real-time market activity on Stocktwits. Join the ABBV message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around AbbVie Inc stock.

ABBV Stock Price Today - Abbvie Inc News, Charts, Retail Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

ABBVAbbvie Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABBV News